



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Lawrence J. Marnett, et al.
Serial No.: 09/924,082
Filed: August 7, 2001
For: Compositions And Methods For Detecting And Quantifying
Cox-2 Activity And Anandamide Metabolites
Group No. 1614
Attorney's Docket No. N-7362 RSM
Customer No. 23456

TECH CENTER 1600/2900

JAN 22 2001

RECEIVED

INFORMATION DISCLOSURE STATEMENT
(SUBMISSION AFTER FILING AN APPLICATION
BUT BEFORE A REJECTION)

Box IDS
Assistant Commissioner for Patents
Washington, D.C. 20231

December 7, 2001

Dear Sir:

Pursuant to 37 C.F.R. §1.97 and §1.98, applicants hereby submit an Information Disclosure Statement for consideration by the Examiner.

I. List of Patents, Publications or other Information

The Patents, publications, or other information submitted for consideration by the Office are listed on the PTO-1449(s), attached hereto.

II. Copies

Submitted herewith is a legible copy of

- (i) each U.S. and Foreign Patent;
- (ii) each publication or that portion which caused it to be listed;
and/or
- (iii) all other information or that portion which caused it to be listed.

III. Concise Explanation of Relevance

The attached documents, publications, and/or other information attached hereto are in the English language and do not require a statement of relevancy.

IV. Fees


The IDS is being filed under 37 C.F.R. §1.97(b); before the mailing date of a first action on the merits (37 C.F.R. §1.97(b)(3)). No fee or statement is required. In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. §1.97(c) and charge our Deposit Account in the amount of \$180.00 as required by 37 C.F.R. §1.17(p).

V. Payment of Fees

No fee is required.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule (with a petition if necessary) and charge the appropriate fee to Deposit Account 23-0035.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit in the overpayment to Deposit Account 23-0035 for any additional fees required under 37 C.F.R. §1.16 or §1.17.


Richard S. Myers, Jr.
Registration No. 42,022
WADDEY & PATTERSON
A Professional Corporation
Customer No. 23456
ATTORNEY FOR APPLICANT


This attorney is located at our Nashville, Tennessee office and can be contacted directly at:

Richard S. Myers, Jr.
Waddey & Patterson
414 Union Street, Suite 2020
Bank of America Plaza
Nashville, TN 37219
(615) 242-2400

CERTIFICATE OF FIRST CLASS MAILING


I hereby certify that this Information Disclosure Statement is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Box IDS, Assistant Commissioner for Patents, Washington, D.C. 20231, December 7, 2001.

Richard S. Myers, Jr.


Registration No. 42,022

12/7/01
Date

RECEIVED

 JAN 22 2001
 TECH CENTER 1600/2900
 Page 1

 Comparable
 Form PTO-1019
 PATENT & TRADEMARK OFFICE

 U.S. Department of Commerce
 Patent & Trademark Office

Atty. Docket N .

Serial No.

 N-7362 RSM
 Customer No. 23456

09/924,082

 INFORMATION DISCLOSURE CITATION
 (Use several sheets if necessary)

Applicant

Lawrence J. Marnett, et al.

 Filing Date
 August 7, 2001

 Group
 1651

Examiner Initial	Document No.	Date	Name	Class	Subclass	Filing Date If Appropriate
AA	3,632,627	January 4, 1972	Gordon, et al.			
AB	4,675,281	June 23, 1987	Lands, et al			
AC	5,047,354	September 10, 1991	Foegh, et al.			
AD	5,162,504	November 10, 1992	Horoszewicz			
AE	5,459,239	October 17, 1995	O'Neill, et al.			
AF	5,474,903	December 12, 1995	Huland			
AG	5,475,021	December 12, 1995	Marnett, et al			
AH	5,543,297	August 6, 1996	Cromlish, et al			
AI	5,589,575	December 31, 1996	Cohen, et al.			
AJ	5,700,654	December 23, 1997	Roberts et al			
AK	5,731,343	March 24, 1998	Feng, et al.			
AL	5,756,092	May 26, 1998	Michelet, et al.			
AM	5,837,479	November 17, 1998	Young, et al.			
AN	5,858,694	January 12, 1999	Piazza, et al.			
AO	5,858,696	January 12, 1999	Roberts, et al.			
AP	5,874,235	February 23, 1999	Chan, et al			
AQ	5,891,622	April 6, 1999	Morrow, et al.			
AR	5,945,675	August 31, 1999	Malins			
AS	5,958,978	September 28, 1999	Yamazaki, et al.			
AT	5,973,191	October 26, 1999	Marnett, et al.			
AU	5,995,645	November 30, 1999	Soenksen, et al.			
AV	5,999,843	December 7, 1999	Anbar			
AW	6,045,773	April 4, 2000	Isakson, et al.			
AX	6,107,049	August 22, 2000	Allard, et al.			


MISCELLANEOUS DOCUMENTS

AY	KALGUTAR, et al.; Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: Facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors; PNAS January 18, 2000; 97(2) 925-930.
AZ	KOZAK, et al.; Oxygenation of the Endocannabinoid, 2-Arachidonylglycerol, to Glycerol Prostaglandins by Cyclooxygenase-2; The Journal of Biological Chemistry October 27, 2000; 43:33744-33749.
BA	KOZAK, et al.; Amino Acid Determinants in Cyclooxygenase-2 Oxygenation of the Endocannabinoid 2-Arachidonylglycerol; JBP Papers in Press June 11, 2001
BB	LANDS, et al.; Phospholipid precursors of prostaglandins; Biochem. Biophys. Acta 1968; 164:426-429.
BC	PRESCOTT; A thematic series on oxidation of lipids as a source of messengers; J.Biol. Chem.; 274:22901.

Examiner:

Date Considered

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Comparable to
R-1449

Atty. Docket No.

Serial No.

N-6138 RSM
Customer No. 23456

09/923,63

Applicant

Lawrence J. Marnett, et al.

Filing Date
August 7, 2001

Group	1651
-------	------

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Examiner
Initial

Document No.

Date _____

Name _____

Class

Subclass

Filing Date
If Appropriate

MISCELLANEOUS DOCUMENTS

BL

VONKEMAN, et al.; The action of prostaglandin synthetase on 2-arachidonyl-lecithin; *Biochem. Biophys. Acta*; 164:430-432.

BM

WOODWARD, et al.; The pharmacology of bimatoprost (Lumigan); *Surv. Ophthalmol.*; 45 Suppl 4; S337-345.

BN

YU, et al; Synthesis of Prostaglandin E2 Ethanolamide from Anandamide by Cyclooxygenase-2; The Journal of Biological Chemistry August 22, 1997; 272(34):21181-21186

Examiner:

Date Considered

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.